

Identification and Cloning of a Novel cDNA Belonging to Tetratricopeptide Repeat Gene Family from Down Syndrome-Critical Region 21q22.2¹

Fujiko Tsukahara,^{*2} Masahira Hattori,[†] Takamura Muraki,^{*} and Yoshiyuki Sakaki[†]

^{*}Department of Pharmacology, Tokyo Women's Medical College, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162; and [†]Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shiroganedai, Minato-ku, Tokyo 108

Received for publication, June 10, 1996

We identified and cloned a novel 9,078-bp cDNA, designated *TPRDI*, from the Down syndrome-critical region by exon trapping. The cDNA encodes a putative protein (TPRDI) of 2,025 amino acid residues. Two isoforms, *TPRDII* (8,992 bp) and *TPRDIII* (7,416 bp), were also isolated. *TPRDII*, which is probably an alternative splicing product from the *TPRD* gene transcript, encodes two large open reading frames (ORFs) of 200 amino acid residues and 1,792 amino acid residues, respectively. *TPRDIII*, which is probably generated by transcription from an alternative start site of the *TPRD* gene, encodes a putative protein of 1,715 amino acid residues (TPRDIII). Northern blot analysis revealed that *TPRDI* and its isoforms are present in 7-17 day mouse embryo and in all the human adult and fetal tissues examined. TPRDI has three units of a 34-amino-acid repeat similar to the tetratricopeptide repeat (TPR) motif, which may mediate interaction with various proteins. A larger ORF encoded by *TPRDII* also has three units of TPR motif, but TPRDIII has only two-thirds of this motif unit. Thus, the *TPRD* gene may belong to the TPR gene family. Near-central and C terminal regions of TPRDs showed some homology to several matrix proteins such as trichohyalin and bullous pemphigoid antigen. It is possible that the *TPRD* gene is one of the genes whose overexpression causes several morphological anomalies observed in Down syndrome.

Key words: cDNA cloning, Down syndrome, exon trapping, tetratricopeptide repeat.

Down syndrome (DS), the most common birth defect, is caused by trisomy of chromosome 21. Cytogenetic and clinical correlations of patients with partial trisomy 21 indicate that a region of 2-4 Mb in 21q22.2 is critical in the pathogenesis of DS (1-3), and this has been designated the Down syndrome-critical region (DCR). Thus, the cloning and characterization of genes in the DCR are important to elucidate the molecular basis of DS. Recently, a transgene study suggested that *Ets2* is involved in some skeletal abnormalities of DS (4). DS manifests complex phenotypes and may be caused by multiple genes. Several genes other than *Ets2*, including *hSIM* (5, 6), *ATP50* (7), *SLC5A3* (8), *KATP-2* (9), *erg* (10), *DSCR1* (11), potassium channel *Isk* (12), and *GABPA* (13), have been identified, but a

number of unknown genes remain to be identified and characterized. For this reason, we have analyzed P1 clones mapped in this region by exon trapping. In this paper, we report a novel gene (cDNA) mapped in the DCR which encodes a protein(s) (230 kDa) possessing tetratricopeptide repeat (TPR) motif.

MATERIALS AND METHODS

Exon Trapping—Several P1 clones possessing a sequence-tagged site in the DCR (14) were isolated from a P1 phage library specific for chromosome 21 (15) by PCR-based screening, and subjected to exon-trapping analysis. The P1 DNA was isolated by the alkaline-SDS method (16), partially digested with *Sau3AI*, and the DNA fragments of 2 to 4 kb were ligated to the *Bam*HI-digested exon trapping vector pEXT3 (17). COS 7 cells were grown to 40-60% confluency and then transfected with the recombinant plasmids by Lipofectin (GIBCO BRL). After incubation at 37°C for 3 days, total RNA was isolated by using an ISOGEN (Nippongene) and subjected to RT-PCR by using primers of the splicing cassette of pEXT3. The PCR products were analyzed by 2% agarose gel electrophoresis and the bands containing the trapped fragments were cloned into pT7 Blue T-vector (Novagen) for sequencing.

Screening of cDNA Libraries—Among many trapped putative exons showing no homology to known genes,

¹This study was supported by Grants-in-Aid for Scientific Research on Priority Areas and for Creative Basic Research (Human Genome Project) from the Ministry of Education, Science, Sports and Culture of Japan, a grant from the Science and Technology Agency (STA) and the H. Yamakawa scholarship fund of Tokyo Women's Medical College. The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL, and GenBank nucleotide sequence databases with the accession numbers D84294 (*TPRDI*), D84295 (*TPRDII*), and D84296 (*TPRDIII*).

²To whom correspondence should be addressed. Phone: +81-3-3353-8111 (Ext. 22513), Fax: +81-3-5269-7417, E-mail: fuji@research.twmc.ac.jp

Abbreviations: DCR, Down syndrome-critical region; DS, Down syndrome; ORF, open reading frame; TPR, tetratricopeptide repeat.

(A)

CTGAACTAGTTGCCAGTGATCTTGAAACGTGACAGTAACCAAGAGATAAATAGGTGACAAATGACAGGAAAATAGATGTAGTAAAAGAGAGTGTGAGA	100
GCAGAAGCTATGGCACTAAAGACTGGATTGAACTCCTTCCTAGCTTGGTGACATGAGCAAATFACTTGATTTAAGTGAGGATTTCCCATCTGTACAGT	200
GGAGTAAACGATAAATGTGCTGCTGAAGAAGAAATGCTGTGAAGATTAGTGAATAATGCAATGTAACAAATTTGGTACAGTATGTGACACATAGTACAAA	300
TGTTTGGCTAGGAAGATGTTATTATCTTCACTTGTGATATTGTGAAAGTTTCATACAGCAAATGGACATCATGAGATGGATTGATTAATAAATAGA	400
TTTGAAGCTCAAGGACTGGTAGTGTCTTGTCTTGGAAAGAAAGAACTTGGTTATCCATAAATAGTAGGATAAATAGTGAAGTATAGGTAACAAGT	500
AATAGTGTTTATGATGCGCTGGTGTATGAGAAAGAAAGCCATTATATGGCAAGAGCTAGAAGTAATAAAAATGGTGCATTTTTCAGTGTATGTTGGC	600
CTATGTAGCTATTCTCTGATAAATAAAAAATCCCTTATTATTGAAGATCTTTCAGGAAAAAAAACCCCTTAGTCTGAAACTTTAGCACCAATCCCCTTG	700
CCCCCATGAAATACGATTTTTTAAACATGGCTTTTGAATAATGTGAGGGTTTTTCCTTTTGGCATTAGCAGTGCTGATTGTGTATTGCGAGTAGTT	800
GTGAGAGCATTAGAAGCAGCAGTCGATAGGAGGATGGAAGGCTGGATGCGCCCTGGGGAGTTAGGAGATTGGCAGACTTACCCTGTACCACTTAGCC	900
CTACTCCTTTGCCAAGACAGAAACACACTGAGATGGATAGGAGAATAATGACAGTGTATAGGAAAGTTCAGTGGAGTCAGGATTTAGGTTAGGCCAG	1000
GAGATGAGAAATAAACAGTTTGTGTATGATGAAATGGCATTTCACAGAAATGACAGTAAAGCAGGTAGGGTACAAGTGCAGCAACAGGAAGATGCTTT	1100
TTCTTCATTCAGCAAACTTATTGAGAGCTTACCATGTGCTAGGCACATACAAAGATAAATAAGATGCCCTTGATGATCCTCTATTAAAGGAGACAT	1200
GTAACAGGTTAACTTAGAGTAGAGATGGTGAATATGTGAACCTGAGGAAAGGAAGAATAGATTAATATCTGGAGAGAGGAAAAGTCAGCAGAAT	1300
GGGACGAGAATCTTCGGAGCTCAGTGTCTGATAGGAGTTATTCCTTGGGCATAGGTTCCAAGTATTTCTAATATACCATAGAAAGCCAGGAAAAC	1400
TTCTTCTGTATCTCAAATGATTTAATTACTGACTTGAGTTTGTGTTGTCTCCTTAGACTTGTGCACCAATGGACAATTTTGTGAGGGAGATTTCACTG	1500
M D N F A E G D F T V	11
TGGCGGATTATGCCTTGTGTAAGATTGCCCTCACGTGGATGATTGTGTCCTTGTGCTGAATTTATGAGCAATGATTATGTCGTGACTCAGCTTTA	1600
A D Y A L L E D C P H V D D C V F A A E F M S N D Y V R V T Q L Y	44
CTGTGATGGGGTGGGTGTGCAATAAAGATTATATCCAAAGTGAAGGAATTTGGAATTTGACATCTGAGTATATGGTGTAGTAAACCAATTTCTGTG	1700
C D G V G V Q Y K D Y I Q S E R N L E F D I C S I W C S K P I S V	77
CTGCAAGATTATGCGATGCCATTAATAAACAATCTTCTGCCCACCTCTGTTTCAACATCAAAACAGTTCCGTAATATCACGATTGCATCCCTGTGTTGG	1800
L Q D Y C D A I K I N I F W P L L F Q H Q N S S V I S R L H P C V D	111
ACGCCAACAAATCACGTGCTTCTGAGATAAATTTGAAGAACTACAACATCTTGAGTTGATGGAAGATATTGTTGGATTGGCAAGAAAGTTGTAATGA	1900
A N N S R A S E I N L K K L Q H L E L M E D I V D L A K K V A N D	144
TTCAATCCTTATTGGAGGCTTATTGAGAATGGTTGTAATAATAGAAAATAAATCTTGGCAATGGAAGAAGCTCTGAATTGGATAAATAATGCAGCGGAT	2000
S F L I G G L L R I G C K I E N K I L A M E E A L N W I K Y A G D	177
GTAACAATCTAATAAATAGGATCAATTTGACAATTTGGCCATGTTAAGATTTTCTTTACTGAATACAAGTACCACATAACTAAAATGTAATGG	2100
V T I L T K L G S I D N C W P M L S I F F T E Y K Y H I T K I V M E	211
AAGACTGCAATTTGCTTGAAGAACTTAAAACCTCAAAGTGTATGAGTGTATAGAGGAAGGAGAACAATGAAATGAAAGGAAATGAAGAGTTTCCAA	2200
D C N L L E E L K T Q S C M D C I E E G E L M K M K G N E E F S K	244
(TPR)	
AGAAAGATTTGATATAGCTATTATCTATTACACAGAGCCATTGAATATAGACCTGAAAACCTACCTTCTTTATGGTAACCGAGCTCTTTGTTTCTTCGT	2300
E R F D I A I I Y Y T R A I E Y R P E N Y L L Y G N R A L C F L R	277
ACTGGACAGTTAGAAATGCACTCGGTGATGGAAGAGAGCCACTATTCTGAAGAACTTGGCCAAAGGGTCATTATCGTTATTGTGATGCTTTTCTA	2400
T G Q F R N A L G D G K R A T I L K N T W P K G H Y R Y C D A L S M	311
TGCTGGGGAATATGACTGGGCCCTGCAAGCAACATAAAAAGCTCAAAAACCTGTGAAAAATGACCCTGAGGGAATCAAGGATCTAATTCAGCAGCATGT	2500
L G E Y D W A L Q A N I K A Q K L C K N D P E G I K D L I Q Q H V	344
AAAGTTACAAAAACAATAGAAGACCTACAAGTCTGAACAGCAAAATAAGGATCCAATTAAGCCCTTTTATGAAAACAGGGCCTACACACCTAGGAGTTTA	2600
K L Q K Q I E D L Q G R T A N K D P I K A F Y E N R A Y T P R S L	377
TCAGACCTATATTTACTACTTCACTTAACTTTGTGGGAAGGAAAGAGATTTTCAGAAAAATTAATCAGGAAATGGCCACGGTGGTAATCAGAACTAA	2700
S A P I F T T S L N F V E K E R D F R K I N H E M A N G G N Q N L K	411
AGGTGGCGGATGAGCGTTGAAGTAGATGATTGTGACTGTCATCCTGAAATTTACCACCATCAAGTCAGCCTCAAAACATAAAGGAAAAACAAAAATC	2800
V A D E A L K V D D C D C H P E F S P P S S Q P P K H K G K Q K S	444
TCGAAACAATGAATCAGAAAAGTTCAGTTCTAGTTCCACTTACCAGCAGATTTGAAGAACAATCTGGAGAAACAGTTTCTAATCTTCCAGA	2900
R N N E S E K F S S S S P L T L P A D L K N I L E K Q F S K S S R	477
GCTGCACACCAGGATTTGCTAATATAATGAAAATGCTGAGAAGCTTAATCAAGATGGCTATATGGCCTTATTGGAGCAGCGTTGCCCGAGCGCTGCAC	3000
A A H Q D F A N I M K M L R S L I Q D G Y M A L L E Q R C R S A A Q	511
AGGCCTTACAGAGTTGCTGAACGGTTAGATCCTCAAAAAATAAGCAATTAAGACTGGCCATGATTAATCTATGTTTGGTCTGCTATGGACTTGCAT	3100
A F T E L L N G L D P Q K I K Q L N L A M I N Y V L V V Y G L A I	544
TTCTCCTTGGAAATAGGACAGCCTGAGGAATATCTGAAGCCGAAAACAGTTTAAAGAGGATTATTGAACACTACCCAGTGAGGGCCTGATTGCTTG	3200
S L L G I G Q P E E L S E A E N Q F K R I I E H Y P S E G L D C L	577
GCCTACTGTGAAATGGAAGAGTATTGAAAAAACAAGATTTCTAGAAGCTCTCAATCACTTTGAGAAAGCAAGAACCTGATTATCGTCTTCTCTG	3300
A Y C G I G K V Y L K K N R F L E A L N H F E K A R T L I Y R L P G	611
GAGTGTAACTGGCCACAGTAATGTGATTATTGAAGAGTCTCAGCCCAAAAAATAAAGATGCTGTTAGAGAAATTTGTTGAAGAATGCAAGTCCC	3400
V L T W P T S N V I I E E S Q P Q K I K M L L E K F V E E C K F P	644
TCAGTGCCAGATGCCATTTGTTGCTATCAGAAGTGGCATGATTTCTAAGATCCAGATATACATAACTGATCCAGACTTAAAGGGTTTATACGCATC	3500
P V P D A I C C Y Q K C H G Y S K I Q I Y I T D P D F K G F I R I	677
AGCTGTTGCCAGTACTGTAATAAGAAATTTACATGAATTTGCTGGAAGAAGTAAAAACTACAACCTTAAATGATAAAAATGACAAGGATTTCTACAAG	3600
S C C Q Y C K I E F H M N C W K K L K T T T F N D K I D K D F L Q G	711
GAATATGCTTACCCCTGACTGTGAAGGTGCTATTTCTAAGATTATCATCTTCCAGCAGTGGTGGTGAAGTAAATGTGAATTTGAACACAAGGTCATAAA	3700
I C L T P D C E G V I S K I I I F S S G E V K C E F E H K V I K	744

Fig. 1 (continued on next page)

AGAAAAGTTCTCCAAGACCTATTCTGAAACAGAAATGTTCTAGCCTAGAGAAACTAAGACTGAAAGAAGACAAAAAATTGAAGAGAAAGATCCAAAAA	3800
<u>E K V P P R P I L K Q K C S S L E K L R L K E D K K L K R K I Q K</u>	777
(M1)	
AAAGAAGCAAAAAGTTAGCACAGAAGAAATGGAGGAGACTTAAGAGAAAGTAATCCACCAAAAATGAAGAGCAGAAGAACTGTAGACAATGTTTC	3900
<u>K E A K K L A Q E R M E E D L R E S N P P K N E E Q K E T V D N V Q</u>	811
AGCGTTGTCAGTTCCTTGATGACAGAATCTACAGTGTATAAAGCAGTATGCTGACAAGATTAATCCGGCATACAGAATACGCCATGCTTCTCAAAGA	4000
<u>R C Q F L D D R I L Q C I K Q Y A D K I K S G I Q N T A M L L K E</u>	844
ATTGCTTTCTGGAAAGTTTGGAGCACAAGACTATACAACCTGTTTTCTAGCAGAAATTTCTAAATGAAGCAGTGGACTATGTTATTCGCCACTTG	4100
<u>L L S W K V L S T E D Y T T C F S S R N F L N E A V D Y V I R H L</u>	877
ATTCAAGAAAATAACAGAGTAAAGACAAGAATATTTCTGCATGTTTTGAGTGAGCTTAAAGAAGTGGAGCCCAATTAGCCGCTGGATCCAAAACTTA	4200
<u>I Q E N N R V K T R I F L H V L S E L K E V E P K L A A W I Q K L N</u>	911
ATAGCTTTGGCTTAGATGCCACAGGAATTTCTTTCTCGTATGGAGCATCTCTTAAACTGCTGATTTTAGTATCATGACTTTCCTCTGGAATGAGAA	4300
<u>S F G L D A T G T F F S R Y G A S L K L L D F S I M T F L W N E K</u>	944
ATATGGTCACAAAAGTACTCTATAGAAGGAAAGCAACTTGATTATTTCTCTGAGCCAGCATCATTGAAGGAAGCCCGTTGTTAATATGGCTGCTAGAA	4400
<u>Y G H K L D S I E G K Q L D Y F S E P A S L K E A R C L I W L L E</u>	977
GAACACAGAGACAAGTTCACAGCATTGCATAGTGCTTTAGATGAATCTTTGATATAAATGGACAGCCGCTGTACTGTGTTAAGGAAACAAGATAGTGGTG	4500
<u>E H R D K F P A L H S A L D E F F D I M D S R C T V L R K Q D S G E</u>	1011
AAGCACCGTTTAGTTCAACCAAGGTGAAAAACAAAAGCAAGAAAAAGCAAGGATTCAAAGCCTATGTTAGTGGGTGCGTGAACAACCTCAGTAAC	4600
<u>A P F S S T K V K N K S K K K K D S K P M L V G S G T T S V T</u>	1044
TTCAAAATAGATCATCACTTCAAGTGAAGACCATAGCAATTCGAAATTCAGATCTGCAGGCCATTTGCAGTGCCTGACCATCTTCGGCAAGATGTA	4700
<u>S N N E I I T S S E D H S N R N S D S A G P F A V P D H L R Q D V</u>	1077
GAAGAATTCGAAGCTCTCTATGACCAACACAGTAACGAATATGTTGTCGCAATAGAAGCTATGGGACATGAACCAAAAACAAAATGTTCAACTCTAT	4800
<u>E E F E A L Y D Q H S N E Y V V R N K K L W D M N P K Q K C S T L Y</u>	1111
ATGATTACTTCTCTCAGTTTTTGGAGAACATGGTCCCTGGACATGAGTAAAGATGTTCTCTGCAGAAATAGAGTTTTTCCAGAAGAACTCGACA	4900
<u>D Y F S Q F L E E H G P L D M S N K M F S A E Y E F F P E E T R Q</u>	1144
GATACTAGAAAAAGCAGGAGTTTAAACCTTTTCTCTGGGATGCCCTGTTTTGTTGATTGACAACTGTAATGCACTGAAGAAGTTGATCACGG	5000
<u>I L E K A G G L K P F L L G C P R F V V I D N C I A L K K V A S R</u>	1177
CTCAAGAAAAAGGAAGAAGAAAAACATTAAAAACAAAGTAGAAGAAATTCAAAAGCAGGGAGTATGTACAGTTAAACTACAAGTGAATCCAGCTG	5100
<u>L K K K R K K K N I K T K V E E I S K A G E Y V R V K L Q L N P A A</u>	1211
CTAGGAATTTAAACAGATGTAAGTCTAAACAGTGTGAGATTCATCTTACGACCAGCTTTTGAAAATGTGAAACCCAAACCTGTCTGCAAAATC	5200
<u>R E F K P D V K S K P V S D S S S A P A F E N V K P K P V S A N S</u>	1244
TCCCAAGCCAGCTTGTGAAGATGTGAAGCCAAACAGTATCCGACAATTTCTCTAGACAAGTTTCTGAGGATGGGCAACCCAAAGGGTCTCTCTAAT	5300
<u>P K P A C E D V K A K P V S D N S S R Q V S E D G Q P K G V S S N</u>	1277
TCTCTAAACAGGCTCTGAGGATGCAAAATACAAGCGAGTCTCCTGTAATCCCCCAACCGGTTCTTGAGGATGTGAAACCAACTTATGGGCTCAAT	5400
<u>S P K P G S E D A N Y K R V S C N S P K P V L E D V K P T Y W A Q S</u>	1311
CCCATTGGTTCACAGGATACTGTACGTATCTTCTTCCAGAGATTGATATCACCCAGACCCGCCAGCATACATAAACGTTTACCAGGTTTGGCCCA	5500
<u>H L V T G Y C T Y L P F Q R F D I T Q T P P A Y I N V L P G L P Q</u>	1344
GTACACCAGCATATACACCCCTGGCCAGCCTTTCTCCTGAATATCAGCTACCAAGATCAGTACCAGTGGTCCGCTTTTTGTAGCCAAATGACAGAGCA	5600
<u>Y T S I Y T P L A S L S P E Y Q L P R S V P V V P S F V A N D R A</u>	1377
GATAAAAATGCTGCTGCCATTTTGGAGGTCATTTGAATGCTGAGAATGTTGCTGGTACCAGATGGCTCTGAAACACAGATCCTTGAGGGCTCTT	5700
<u>D K N A A A Y F E G H H L N A E N V A G H Q I A S E T Q I L E G S L</u>	1411
TGGGAATATCTGTAAGTACACTGCAGCAGGATGCTCATAAGTCTGAGTGTCTAACAGAAATGATGAGCACTGTGAAATTTCTAACAAACA	5800
<u>G I S V K S H C S T G D A H T V L S E S N R N D E H C G N S N N K</u>	1444
ATGTGAAGTAATCCAGAAAGCACCAGTGCAGTAAACAATTCACACGTGCAGATGGTGGCATACAGGTATCTTGAACATAATACACCAAGAAGTC	5900
<u>C E V I P E S T S A V T N I P H V Q M V A I Q V S W N I I H Q E V</u>	1477
AATACTGAGCCATATAATCCTTTTGGAGACGACAAGGGAAATTCACGGATGAAAAGGAGCACCAGTATTACAAGACCACTTCAAGAAGTGTATG	6000
<u>N T E P Y N P F E E R Q G E I S R I E K E H Q V L Q D Q L Q E V Y E</u>	1511
(M2)	
AAAATTATGAGCAGATAAACTTAAGGGCTTAGAAGAGACCAGGACCTGGAAGAGAAGTTGAAAAGGCACTTAGAAGAAAAACAAGATCTCAAAGCGGA	6100
<u>N Y E Q I K L K G L E E T R D L E E K L K R H L E E N K I S K T E</u>	1544
ATTAGATTGGTTCTTCAAGATTTGAAAGAGAAAATTAATAAATGGCAACAGGAAAAAAGAAATCCAAAGAACTAAAACTACTGAAGAAGAAAAT	6200
<u>L D W F L Q D L E R E I K K W Q Q E K K E I Q E R L K S L K K K I</u>	1577
AAAAAGTTTCAAATGCCAGTGAATGTATACCCAGAAAATGATGGAAGGAAAAAGAAACATGAATTACATCTGGATCAGTCCCTTGAATCAGCAACA	6300
<u>K K V S N A S E M Y T Q K N D G K E K E H E L H L D Q S L E I S N T</u>	1611
CACCTACAAATGAGAAAATGAAAATAGAAGATATATAAAGAAGGAAAGAGGATTATGAAGAGAGTATCAGAGAGCTGTGGCTGCAGAGGTATCCGT	6400
<u>L T N E K M K I E E Y I K K G K E D Y E E S H Q R A V A A E V S V</u>	1644
ACTTGAACCTGGAAGGAGAGTGAAGTGTATAAGCTACAGATCATGGAGTACAAGCAGAAGCCTTCTGAAGAAGCTGGGGCTGATTAGCCGTGATCCT	6500
<u>L E N W K E S E V Y K L Q I M E S Q A E A F L K K L G L I S R D P</u>	1677

Fig. 1 (continued on next page)

several exons isolated from a P1 clone (T1212) hit by a STS marker 238wc3 (14) were found to hybridize with large transcripts of about 7.4 and 9 kb. These exons were then used as probes to screen the human fetal brain and heart cDNA libraries (Clontech). Hybridization was performed with ³²P-labeled probes under appropriate conditions. The filters were washed with 0.1×SSC, 0.1% SDS at 65°C and analyzed by using the Fuji Bio Imaging Analyzer BAS2000 system. The positive cDNA clones were sequenced and overlapped. The terminal regions of the overlapped sequences were furthermore used as probes to obtain the extended clones. The 5' and 3' ends of the cDNA were also isolated by the 5' and 3' rapid amplification of cDNA ends

system (5' RACE and 3' RACE, GIBCO BRL) under the conditions recommended by the supplier.

Northern Blot Analysis—The ³²P-labeled probe from a region common to *TPRDI* and its isoforms (nt 2711–3222 of *TPRDI*) was hybridized to 2 μg of poly(A)⁺ RNA isolated from several tissues of human fetus or adult or from 7–17 day mouse embryo (Clontech). After hybridization under appropriate conditions, the filters were washed with 0.1×SSC, 0.1% SDS at 65°C and analyzed by using the Fuji Bio Imaging Analyzer BAS2000 system.

RT-PCR—To prove the existence of *TPRDII*, RT-PCR was performed with primers flanking the presumed deletion by alternative splicing (5'-ATGGAAGATATTGTGG-

GCAGCATATCCTGACATGGAGTCTGATATACGTTTCATGGGAATTGTTTCTTTCTAATGTTACAAAAGAAATTGAGAAAGCAAAGTCTCAGTTTGAAGAAC	6600
A A Y P D M E S D I R S W E L F L S N V T K E I E K A K S Q F E E Q	1711
AAATTAAGGCAATTAATAAATGGTTCTCGGCTCAGTGAACCTTCTAAAGTGCAGATTCTGAGCTTTCATTCTCGCTGTAACACGGTTCATCCCGAGTT	6700
I K A I K N G S R L S E L S K V Q I S E L S F P A C N T V H P E L	1744
ACTCCCTGAGTCTTCAGGCCACGATGGCCAAGGGCTTGTGACTTCTGCAAGGACGCTGACTGGAACCCACGCAGCACTTCACAGGGATCCTAGTGTGTTT	6800
L P E S S G H D G Q G L V T S A S D V T G N H A A L H R D P S V F	1777
TCTGCTGGTGATCCCCAGGGGAGGCTCCTTCTGCGTGTGGCAGGGCCACCCCTGGTCTGAGCTGAAGCCACTCAGCTGACAGGGCCAAAACGGGCTG	6900
S A G D S P G E A P S A L L P G P P P G Q P E A T Q L T G P K R A G	1811
GCCAGGCAGCTCTGTGAGAACGAGCCCTGTGGCTGATCGGAAGCAGCCTGTTCCTCCAGGACGTGCTGGCGTTCAGGCAGTCTCCAAAAAGCCGTT	7000
Q A A L S E R S P V A D R K Q P V P P G R A A R S S Q S P K K P F	1844
CAATAGTATTATTGAGCACCTGTGAGTGTATCCCATGTTACAACAGCACTGAGCTTGTGTTTTATTAAAAAAGTGGGAAGCAAAAACAAGAATCA	7100
N S I I E H L S V V F P C Y N S T E L A G F I K K V R S K N K N S	1877
CTCTCAGGATTGAGTATTGATGAAATGTCCAAAGAGTGACAGAACACATTCTAGATGAACAGAAAAAGAAAAGCCAAACCCAGGAAAGGACAAAGAGGA	7200
L S G L S I D E I V Q R V T E H I L D E Q K K K K P N P G K D K R T	1911
CTTATGAGCCCACTCTGCCACCCCGTGACCAGGTCCTCCAGGGCTCACCCCTCGVTGGTGTGTCACCATCACCCAAACCCAGGGGCGAGAAAGCAGA	7300
Y E P S S A T P V T R S S Q G S P S V V V A P S P K T K G Q K A E	1944
AGATGTCCTGTGAGGATTGCACTGGGTGCAAGTCTCTGTGAAATATGCCACGAGGTGTTCAAATCAAAAACGTCGGTGTGCTCAAATGTGGGCACAAG	7400
D V P V R I A L G A S S C E I C H E V F K S K N V R V L K C G H K	1977
TATCACAAGGGTGTCTTAAGCAGTGGCTTAAAGGGCAGAGCGCTTCCCGGCTGCCAGGGTGTGATCTCCTGACAGAAGATCACCTTCTGGAAGAG	7500
Y H K G C F K Q W L K G Q S A C P A C Q G R D L L T E E S P S G R G	2011
GCTGGCCAGTCAGAATCAGGAGCTGCCTTCTGCTTCTTAGTGTAGTACACATTTCAATGTCATCCACCAGTGTGTTGAATCCGAAGAATGACAA	7600
W P S Q N Q E L P S C S S R *	2025
TTTTCTACCAGTGGTGTAAAAACAACATTTGAAGACCCTTGTGCATTTGTGTGCACAAAGCTAAATACATGGAATCGTTAATATCGTGATATTAAG	7700
TAATTTCCCACTCTGAGTGAATCTTTGATGATTGCCAACAGTGGCTAAATAAATGACGGCTACCACATCATGGTCTACTGGGGTGGCAGGGCTCT	7800
TTGAGGTTGGTGGCTTCTTTTGGAAAGTACTATGAACGCTCTCGAAGCAGTATCTAGTGAAGAATCTTAACATAGCCAAGCGCCACAGTTTGTTC	7900
CCAGCTTTTCCCTTTCTGTTTGA AAAACCTTCTCTGGTAGCTCCACAAGAGAGATGATACTGACTTTTAAATTTTACAAAGACTCTGATTCCT	8000
GATATGCCTATATTTTCCCAAGATTCTGCATTTAAGGATGGGCATAAGCAAATATATTTAATAATTTATAGTTAATGTTAAATATTGGCTGAT	8100
TTAGACAAAAGATTCAAATCTCCTCTTTGTGAAATCCCATCTGCATTTGATTTTTATTATTTATGTTCCCCCGTTAGATTGTTTAAAGTGTTTGCTT	8200
CTACCTTTTATAGATGTAATCTGATTTTCAAAAATCATTAAACATTTTAAATAGTATCGACTAAGACTTTTCCCCCTGGAATCGAGGCTGTGTCTC	8300
GTATCCAGCCCGGTTGGAGCCTGCTCTTTGAACCTCGCTGCCCTTCCCTAGCAGCTTCTGTCTTCTGTGAGTCACTGAGGAGTGTGGGATC	8400
CGCATCCAGCCGTGTGAGCACACAACAGGCTGTGTGGAATGGCCACCACATCTCTTCCCAACCCACCACAAAAGAGAAGCTGTGCTTTAG	8500
ACAACCTCGAGGTATCTGTGTTACAATCGTTCTGTGTTGATATTTGTGTAAGTATGCATGCAGTCTGTACTGTGACCTAAGAACAACAACTGTAACCTG	8600
CATTAGAAACCATGAAAAAATAGATATGTTTGTGACTTTTAGACAGTGGTAAATATAGAACCATGAATCTGGTCACATTCATTTCTCTCAACAT	8700
GAAGGATCAAAAATGTTTTCAATGTGTTCTTTGTTCCACTGGAACCTAGAGTCAATGAGTTATGAGCTGATTTGGTCACTTCCCTCTGCCTTTGTTT	8800
ACTGTGAGTCTGATGCTTAGTGACTTAGTTCTTAGAAGCTCAGCCTTAGTTTGAACAGATTCTCCACGGTGTCCCAAAACACTGTCTGCATATC	8900
CATAAGAAATGAGCGCTATGGGTGTTAACTGTCATGAGGATCAGTTTGCAGCAGCAAGTACAAAAGGAGAAGGAACATCCCTTGAATGAGTGTGTTTT	9000
GTACATAACTTCAGATACCTGTGAACATGCCTATATTTGTCCAACAACCTGTGAGATAAAGAACATTTCTAAAATGAG	9078
(B)	
TACATTTGGAAAGTCTTACTGACATGCAGAAAATAGTACAGAAAAACATACAAAATAGGAATGTTATTGGCTGGGCATGGTGGCTCACACCTGTAATCCCGAG	100
CAGTTTGGGAGGCCAAGGCGGGTGGATCCAGAAGGTCAGGAGATCGAGACCATCGTGGCTAACATGGTGAAACCCCTGGTCCCTACTAAAAAATTCAAAAAAT	200
AGCCAGGTGACTGGCATGTGCTGTAATCCAGCTACTTGGGAGGCTGAGGCAGGAGATCACTTGAACCCGGGAGCAAGGTTGCAGTGTAGCCAAAGATC	300
AGCCCACTGCAGCTCCAGCCTGGCCGACAGAGCGAGACTCTGTCTCAAAAAAACAAGAAATGCTATGCATAGGTACAATGTGCAAAATGCAAGAAATA	400
CTTCAGAAATATTAAGTAGTTATTCCGGGTAGTTGTGATTTGACTCTGGGTGACTTTTCCCTTTGTTTATTTTCTGATTTTCCAAATTTCT	500
ATAATGGACATATATATATGATTTTTTTTAAATAAAATATCTTTGACTAGATAATATACATGGAAAATTCACAAAGTACACATATGCAAGATATAA	600
TACTTTTACTATAAAAGAGTGAATAATTTTAAATACTGTTTTTCTTTTATG	652

Fig. 1. (A) Nucleotide and deduced amino acid sequences of *TPRDI*. The ATG initiation and the TAG stop codons and a poly A signal are underlined. TPR motif (aa 234–335) and two regions showing some homology to matrix proteins (aa 750–850 and aa 1480–1640) are double-underlined and indicated by TPR, M1, and M2, re-

spectively. (B) A unique 5'-end sequence (852 nt) of *TPRDIII*. An Alu-like sequence (nt 80–345) is underlined and indicated by Alu. Nucleotide and amino acid residues are numbered on the right, and one-letter amino acid designations are used.

ATTTGG-3' and 5'-CTAAACTGTCCAGTACGAAGA-3' corresponding to nt 1860-1881 and nt 2294-2314 of *TPRDI*, respectively). cDNA libraries of human fetal brain, heart, and kidney (Clontech) were used as templates. PCR involved was denaturation at 94°C for 5 min, followed by 30 cycles of amplification at 94°C for 1 min, 54°C for 1 min and 72°C for 1 min, with a final elongation at 72°C for 10 min. The RT-PCR products were analyzed by 2% agarose gel electrophoresis and subcloned into pT7 Blue T-vector (Novagen) for sequencing.

Sequence Analysis—DNA sequencing was performed by the dideoxy chain terminator method (18) and analyzed by HITACHI SQ-5500 and ABI 373A sequencers. Both strands of isolated cDNA clones were sequenced. Three or more separate subclones of the PCR product were sequenced to rule out the possibility of any Taq polymerase errors. The sequence alignments were done by using a computer software program, GENETYX-MAC/ATSQ, and the deduced amino acid residues were analyzed by GENETYX-MAC (Software Development, Tokyo). Sequence identity search was carried out with the BLAST program in databases: GenBank (release 92.0), EMBL (release 45), SwissProt (release 32.0), PIR (release 47.0), and PRF (release 96-01).

RESULTS AND DISCUSSION

We identified several possible exons from a P1 clone (T1212) hit by a STS marker 238wc3 in DCR (14) by exon trapping. They showed no homology to human genes. Northern analysis using these exons revealed two large transcripts of about 7.4 and 9 kb. To isolate a full-length clone, we then screened human fetal brain and heart cDNA libraries by plaque hybridization using these trapped exons as probes. In combination with 5' and 3' RACE, we finally

obtained a novel cDNA of 9,078 bp, designated *TPRDI*.

TPRDI possesses a 5'-untranslated sequence of 1,469 nt followed by a single large open reading frame (ORF) of 6,075 nt and a 3'-untranslated sequence of 1,534 nt with a polyadenylation signal (AATAAA) 17 nt before the 3'-end (Figs. 1A and 2). The sequence around the initiation codon has the most favorable translation initiation sequence ACCATGG (19). Thus, we concluded that *TPRDI* encodes a putative protein of 2,025 amino acid residues (*TPRDI*) with a calculated molecular mass of 230 kDa and pI of 7.3. The expression sequence tags (ESTs) in 21q22.2, 21ES-0203, and 21ES0084 (20), are present at nt 5933-6075 and




Fig. 3. RT-PCR analysis of *TPRDI* and *TPRDII*. RT-PCR was performed with primers flanking the presumed deletion by alternative splicing. PCR products were electrophoresed in a 2% agarose gel and stained with ethidium bromide. Two RT-PCR products of 455 and 369 bp corresponding to sequences from *TPRDI* and *TPRDII*, respectively, were detected in human fetal brain, heart, and kidney. The size markers (M) are ϕ X174-*Hae*III digest.




Fig. 2. Schematic comparison of the *TPRD* gene transcripts. ORFs of *TPRDI*, *TPRDII*, and *TPRDIII* are indicated by box columns and the non-coding regions are indicated by bars. Three units of TPR motifs (TPR) are half-toned and the regions showing some homology to matrix proteins (M1 and M2) are shown by filled boxes. *TPRDII* has a small deletion sequence of 86 nt and *TPRDIII* has a unique 5'-end sequence of 652 nt which is indicated by half-tone. See text for further detail.

nt 8546-8915, respectively. Thus, the *TPRD* gene is mapped to DCR.

We also isolated cDNA isoforms of *TPRDI*, designated *TPRDII* (8,992 bp) and *TPRDIII* (7,416 bp) (Fig. 1, A and B, and Fig. 2). *TPRDII* had a small deletion from nt 2071 to 2156 in comparison with *TPRDI*. As shown in Fig. 3, two RT-PCR products of 455 and 369 bp, corresponding to sequences from *TPRDI* and *TPRDII*, respectively, were detected in human fetal brain, heart, and kidney by using primers flanking this deletion. Thus, *TPRDII* is probably an alternative splicing product from the *TPRD* gene transcript. This small deletion generated a stop codon TGA so that *TPRDII* has two putative ORFs: one ORF of 600 nt begins at the same initiator codon in *TPRDI* and ends at the newly generated stop codon, and the other ORF of 5,376 nt begins at a possible initiator codon (ATG) at nt 2169-2171. It remains to be elucidated which ORF(s) is really translat-

ed into protein(s). In contrast, *TPRDIII* has a different 5'-end sequence of 652 nt which is connected to adenosine residue at nt 2315 of *TPRDI*, suggesting that it is generated by transcription from an alternative start site of the *TPRD* gene. Since the different 5'-end sequence of *TPRDIII* was mapped back to the original P1 clone (T1212), it may not be a cloning artifact. Thus, *TPRDIII* possesses a 5'-untranslated sequence of 737 nt, followed by a single ORF of 5,145 nt which begins at a possible initiator codon (ATG) at nt 2400-2402 in *TPRDI*. Therefore, *TPRDIII* encodes a putative protein of 1,715 amino acid residues (TPRDIII) with a calculated molecular mass of 194 kDa and pI of 8.0. It is of interest to note that the 5'-untranslated sequence of *TPRDIII* has an Alu-like sequence.

As shown in Fig. 4, Northern blot analysis showed that a probe from an identical region among these isoforms (nt 2711-3222) revealed two bands, one at the position of 9 kb




Fig. 4. Northern blot analysis of the *TPRD* gene. The radiolabeled probe from a region common to *TPRDI* and its isoforms (nt 2711-3222 in *TPRDI*) was hybridized to poly(A)⁺ RNAs (2 μg) isolated from several tissues of human fetus and adult and from 7-17 day mouse embryo (Clontech). Two bands, one at the position of approximately 9 kb corresponding to *TPRDI* and *TPRDII* and the other at approximately 7.4 kb for *TPRDIII*, were observed in all the tissues examined. A β-actin control for RNA integrity is shown at the bottom. The size marker is indicated to the left of the figures.




Fig. 5. Characterization of the TPR motif in *TPRDI*. The TPR motifs in *TPRDI*, serine/threonine phosphatase of human (hPPT) (21) and rat (rPPT) (22), human IEF SSP 3521 (IEF) (23) and *S. cerevisiae* STI1 (24) are aligned in terms of the consensus TPR sequence (31). IEF SSP 3521 and STI1 have two TPR motifs. Residues identical to *TPRDI* are boxed. The asterisks in the consensus TPR sequence indicate any hydrophobic residues. The position of the first amino acid residue of each TPR is given in parentheses.




Fig. 6. Hydropathy analysis of TPRDI. Hydropathy plot was made according to Hopp and Woods (28) with a window of 5 residues. Four hydrophobic regions which might be transmembrane regions are indicated by asterisks.

corresponding to *TPRDI* and *TPRDII*, and the other at approximately 7.4 kb for *TPRDIII*. The transcripts of the *TPRD* gene were expressed in 7–17 day mouse embryo and in all the human fetal and adult tissues examined.

Protein database searches for the predicted protein, TPRDI, using the BLAST program revealed the tetratricopeptide repeat (TPR) motif homologous to three units of a 34-amino-acid repeat in several proteins, including serine/threonine phosphatase of human (21) and rat (22), human transformation-sensitive protein IEF SSP 3512 (23) and yeast heat shock protein STI1 (24), in an N-terminal region (aa 234–335) (Figs. 2 and 5). The TPR consensus sequence is well conserved in TPRDI. A larger ORF encoded by *TPRDII* also has three units of TPR motif, but *TPRDIII* has only two-thirds of this motif unit. In addition, the near-central and C terminal regions of TPRDI (aa 750–850 and aa 1480–1640), which are predicted to have α -helical structures by the Chou-Fasman analysis (25), also showed some homology to several peptide repeat regions of several matrix proteins, such as human trichohyalin, an intermediate filament-associated protein (26), human bullous pemphigoid antigen, an adhesion junction plaque protein (27), and myosin heavy chain of several species. A larger ORF encoded by *TPRDII* and *TPRDIII* also have these regions. Hydropathy analysis using Hopp and Woods hydropathy plot (28) revealed four hydrophobic regions, which might be transmembrane domains (Fig. 6). These data suggest that the *TPRD* gene belongs to the TPR gene family and encodes a matrix protein containing transmembrane structure.

The TPR motif was initially identified in several cell-division cycle gene products (*cdc16*, *cdc23*, *nuc2⁺*, *bimA*) and proteins involved in the regulation of RNA synthesis (*SSN6*, *SKI3*) (29–32). Now it has been found in about 20 different proteins. It has been suggested that TPR-containing proteins physically interact with themselves, with each other and with the cytoskeleton *via* their TPR domains (30, 32). Some TPR-containing proteins may interact functionally with proteins containing a 43-amino-acid repeat called the beta-transducin repeat (30). It is possible, therefore, that the overexpression of the *TPRD* gene causes imbalance of the protein-protein interaction during cell growth and differentiation, and consequently leads to several morphological anomalies observed in Down syndrome. Recently, Ohira *et al.* also identified a novel cDNA of 9,045 bp, designated *TPRD*, from the same P1 clone (33). Their *TPRD* may be an another cDNA isoform, since it has a different 5' end sequence of 1,385 nt which is connected to

adenosine residue at nt 1459 of *TPRDI*. Further study will clarify the role of these isoforms in the pathogenesis of Down syndrome.

REFERENCES

- Delabar, J.-M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J.-L., Prieur, M., Noel, B., and Sinet, P.-M. (1993) Molecular mapping of twenty-four features of Down syndrome on chromosome 21. *Eur. J. Hum. Genet.* 1, 114–124
- Rahmani, Z., Blouin, J.-L., Creau-Goldberg, N., Watkins, P.C., Mattei, J.-F., Poissonnier, M., Prieur, M., Chettouh, Z., Nicole, A., Aurias, A., Sinet, P.-M., and Delabar, J.-M. (1989) Critical role of the *D21S55* region on chromosome 21 in the pathogenesis of Down syndrome. *Proc. Natl. Acad. Sci. USA* 86, 5958–5962
- Korenberg, J.R., Kawashima, H., Pulst, S.-M., Ikeuchi, T., Ogasawara, N., Yamamoto, K., Schonberg, S.A., West, R., Allen, L., Magenis, E., Ikawa, K., Taniguchi, N., and Epstein, C.J. (1990) Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. *Am. J. Hum. Genet.* 47, 236–246
- Sumarsono, S.H., Wilson, T.J., Tymms, M.J., Venter, D.J., Corrick, C.M., Kola, R., Lahoud, M.H., Papas, T.S., Seth, A., and Kola, I. (1996) Down's syndrome-like skeletal abnormalities in *Ets2* transgenic mice. *Nature* 379, 534–537
- Chen, H., Chrast, R., Rossier, C., Gos, A., Antonarakis, S.E., Kudoh, J., Yamaki, A., Shindoh, N., Maeda, H., Minoshima, S., and Shimizu, N. (1995) *Single-minded* and Down syndrome? *Nature Genet.* 10, 9–10
- Dahmane, N., Charron, G., Lopes, C., Yaspo, M.-L., Maunoury, C., Decorte, L., Sinet, P.-M., Bloch, B., and Delabar, J.-M. (1995) Down syndrome-critical region contains a gene homologous to *Drosophila sim* expressed during rat and human central nervous system development. *Proc. Natl. Acad. Sci. USA* 92, 9191–9195
- Chen, H., Morris, M.A., Rossier, C., Blouin, J.-L., and Antonarakis, S.E. (1995) Cloning of the cDNA for the human ATP synthase OSCP subunit (ATP50) by exon trapping and mapping to chromosome 21q22.1-q22.2. *Genomics* 28, 470–476
- Berry, G.T., Mallee, J.J., Kwon, H.M., Rim, J.S., Mulla, W.R., Muenke, M., and Spinner, N.B. (1995) The human osmoregulatory Na^+ /*myo*-inositol cotransporter gene (*SLC5A3*): Molecular cloning and localization to chromosome 21. *Genomics* 25, 507–513
- Tsaur, M.-L., Menzel, S., Lai, F.-P., Espinosa III, R., Concannon, P., Spielman, R.S., Hanis, C.L., Cox, N.J., Le Beau, M.M., German, M.S., Jan, L.Y., Bell, G.I., and Stoffel, M. (1995) Isolation of a cDNA clone encoding a K_{ATP} channel-like protein expressed in insulin-secreting cells, localization of the human gene to chromosome band 21q22.1, and linkage studies with NIDDM. *Diabetes* 44, 592–596
- Rao, V.N., Papas, T.S., and Reddy, E.S.P. (1987) *erg*, a human *ets*-related gene on chromosome 21: Alternative splicing, polyadenylation, and translation. *Science* 237, 635–639

11. Fuentes, J.-J., Pritchard, M.A., Planas, A.M., Bosch, A., Ferrer, I., and Estivill, X. (1995) A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. *Hum. Mol. Genet.* **4**, 1935-1944
12. Malo, M.S., Srivastava, K., and Ingram, V.M. (1995) Gene assignment by polymerase chain reaction: Localization of the human potassium channel I_{Kr} gene to the Down's syndrome region of chromosome 21q22.1-q22.2. *Gene* **159**, 273-275
13. Chrasti, R., Chen, H., Morris, M.A., and Antonarakis, S.E. (1995) Mapping of the human transcription factor *GABPA* (*E4TF1-60*) gene to chromosome 21. *Genomics* **28**, 119-122
14. Chumakov, I., Rigault, P., Guillou, S., Ougen, P., Billaut, A., Guasconi, G., Gervy, P., LeGall, I., Soularue, P., Grinas, L., Bougueleret, L., Bellanné-Chantelot, C., Lacroix, B., Barillot, E., Gesnoui, P., Pook, S., Vaysseix, G., Frelat, G., Schmitz, A., Sambucy, J.-L., Bosch, A., Estivill, X., Weissenbach, J., Vignal, A., Riethman, H., Cox, D., Patterson, D., Gardiner, K., Hattori, M., Sakaki, Y., Ichikawa, H., Ohki, M., Paslier, D.L., Heilig, R., Antonarakis, S., and Cohen, D. (1992) Continuum of overlapping clones spanning the entire human chromosome 21q. *Nature* **359**, 380-387
15. Tanahashi, H., Ito, T., Hattori, M., Ohira, M., Ohki, M., Tashiro, K., and Sakaki, Y. (1994) Sixty new STSs (sequence-tagged sites) of human chromosome 21. *DNA Res.* **1**, 85-89
16. Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
17. Ozawa, N., Kano, T., Taga, C., Hattori, M., Sakaki, Y., and Suzuki, H. (1993) An exon-trapping system with a newly constructed trapping vector pEXT2; its application to the proximal region of the human chromosome 21 long arm. *FEBS Lett.* **325**, 303-308
18. Sanger, F., Nicklen, S., and Coulson, A.R. (1977) DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**, 5463-5467
19. Kozak, M. (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. *Cell* **44**, 283-292
20. Cheng, J.-F., Boyartchuk, V., and Zhu, Y. (1994) Isolation and mapping of human chromosome 21 cDNA: Progress in constructing a chromosome 21 expression map. *Genomics* **23**, 75-84
21. Chen, M.X., McPartlin, A.E., Brown, L., Chen, Y.H., Barker, H.M., and Cohen, P.T.W. (1994) A novel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. *EMBO J.* **13**, 4278-4290
22. Becker, W., Kentrup, H., Klumpp, S., Schultz, J.E., and Joost, H.G. (1994) Molecular cloning of a protein serine/threonine phosphatase containing a putative regulatory tetratricopeptide repeat domain. *J. Biol. Chem.* **269**, 22586-22592
23. Honoré, B., Leffers, H., Madsen, P., Rasmussen, H.H., Vandekerckhove, J., and Celis, J.E. (1992) Molecular cloning and expression of a transformation-sensitive human protein containing the TPR motif and sharing identity to the stress-inducible yeast protein *STI1*. *J. Biol. Chem.* **267**, 8485-8491
24. Nicolet, C.M. and Craig, E.A. (1989) Isolation and characterization of *STI1*, a stress-inducible gene from *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **9**, 3638-3646
25. Chou, P.Y. and Fasman, G.D. (1974) Prediction of protein conformation. *Biochemistry* **13**, 222-245
26. Lee, S.-C., Kim, I.-G., Marekov, L.N., O'Keefe, E.J., Parry, D.A.D., and Steinert, P.M. (1993) The structure of human trichohyalin. *J. Biol. Chem.* **268**, 12164-12176
27. Tanaka, T., Parry, D.A.D., Klaus-Kovtun, V., Steinert, P.M., and Stanley, J.R. (1991) Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin I confirms that they define a new family of cell adhesion junction plaque proteins. *J. Biol. Chem.* **266**, 12555-12559
28. Hopp, T.P. and Woods, K.R. (1981) Prediction of protein antigenic determinants from amino acid sequences. *Proc. Natl. Acad. Sci. USA* **78**, 3824-3828
29. Boguski, M.S., Sikorski, R.S., Hieter, P., and Goebel, M. (1990) Expanding family. *Nature* **346**, 114
30. Goebel, M. and Yanagida, M. (1991) The TPR snap helix: a novel protein repeat motif from mitosis to transcription. *Trends Biochem. Sci.* **16**, 173-177
31. Hirano, T., Kinoshita, N., Morikawa, K., and Yanagida, M. (1990) Snap helix with knob and hole: Essential repeats in *S. pombe* nuclear protein *nuc2+*. *Cell* **60**, 319-328
32. Sikorski, R.S., Michaud, W.A., Wootton, J.C., Boguski, M.S., Connelly, C., and Hieter, P. (1991) TPR proteins as essential components of the yeast cell cycle. *Cold Spring Harbor Symp. Quant. Biol.* **56**, 663-673
33. Ohira, M., Ootsuyama, A., Suzuki, E., Ichikawa, H., Seki, N., Nagase, T., Nomura, N., and Ohki, M. (1996) Identification of a novel human gene containing the tetratricopeptide repeat domain from the Down syndrome region of chromosome 21. *DNA Res.* **3**, 9-16